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Objective: To investigate short-term efﬁcacy and safety of a novel lipid ibuprofen formulation 1200 mg/
day compared with standard ibuprofen 1200 mg/day and 2400 mg/day in episodic knee arthralgia/ﬂaring
pain.
Design: Multicentre, randomised, double-blind, 3-arm, non-inferiority trial conducted at 27 primary care
centres. Adults with 1 knee ﬂare episode within 12 months were recruited within 24 h of new ﬂare
with pain severity 5 on a 0e10 numerical rating scale (NRS). Primary outcome was change from
baseline in WOMAC pain subscale over 5 days. Main secondary outcome was Gastrointestinal Symptom
Rating Scale (GSRS) change from baseline. Other endpoints included assessment of WOMAC total sub-
scale scores and self-reported NRS for pain, subject nominated activity, stiffness and swelling.
Results: 462 patients were enrolled (58.9% males; mean age 52.2 years). Treatment allocation comprised
148 lipid 1200 mg, 155 soft-gel 1200 mg, 159 soft-gel 2400 mg. WOMAC pain subscale scores decreased
in all groups, with lipid 1200 mg being non-inferior to soft-gel 1200 mg (adjusted mean difference 0.26
[95% conﬁdence interval [CI] 0.69, 0.17]) and to soft-gel 2400 mg (difference 0.19 [95% CI 0.24, 0.62]).
No differences were seen in mean GSRS total scores. NRS secondary endpoints suggested greater im-
provements in the lipid 1200 mg group compared to soft-gel 1200 mg, with similar results to soft-gel
2400 mg. The most frequent drug-related adverse events (AEs) were gastrointestinal (GI) disorders,
with statistically fewer events for lipid 1200 mg vs soft-gel 2400 mg (P ¼ 0.01, post-hoc analysis).
Conclusions: Ibuprofen 1200 mg/day lipid formulation was non-inferior to standard ibuprofen soft-gel
capsules 1200 mg and 2400 mg/day in relieving ﬂaring knee pain. NRS endpoints showed lipid
1200 mg was numerically similar to soft-gel 2400 mg.
Trial registration number: EudraCT number: 2014-004254-33.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).to: S.M.A. Bierma-Zeinstra,
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Frequent knee pain affects approximately 25% of adults >55
years,1,2 limiting function and mobility, and results in reduced
quality of life.3 The aetiology is often unknown, although osteoar-
thritis (OA) is the most common joint disease, particularly in older
adults.search Society International. This is an open access article under the CC BY-NC-ND
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the natural history of knee OA6 and may occur in early and
advanced disease.4 Symptoms may be characterised by abrupt
changes and short-term ﬂuctuations.7 Early stage OA is charac-
terised by such ﬂare-ups usually brought on by a trigger, e.g., an
unusual activity or movement, but has limited impact.4 The path-
ological process underlying these episodic ﬂares is unclear,
although associationwith physician-assessed effusion, patient self-
reported swelling, and changes in synovial ﬂuid composition imply
an inﬂammatory component.5,8 Fluctuating pain is also associated
with change in effusion or synovitis scores assessed on magnetic
resonance imaging (MRI).9
Pharmacological OA treatments include analgesics, non-
steroidal anti-inﬂammatory drugs (NSAIDS), intra-articular corti-
costeroids, and opioids, all of which have been shown to provide
effective pain relief compared to placebo10 and NSAIDs offer similar
pain relief to opioids in OA patients.11 However, few studies have
addressedmanagement of knee pain ﬂare. Given the predominance
of pharmacological management for OA,12,13 it is likely that similar
agents are commonly used for acute episodes of knee pain. NSAIDs
are the commonest OA therapy, with ibuprofen being the most
commonly prescribed.14,15 It is well-tolerated with a well-
established safety proﬁle; the most common adverse effects (AEs)
are gastrointestinal (GI) (estimated incidence of 12.1%).16 Ibuprofen
shows the lowest rate of GI side-effects compared to other NSAIDs,
with these being dose-related.17 A recent review of the cardiovas-
cular risks associated with use of NSAIDs by regulatory authorities
has shown these to be dose- and time-dependent.18 Unlike the
lower doses (1200 mg/day), high daily doses of ibuprofen
(2400 mg/day) are associated with increased risk of cardiovascular
events (myocardial infarction [MI] and stroke).19 These ﬁndings are
supported by a recent white paper in OA20 and a meta-analysis on
the risk of acute MI with NSAIDs.21 Thus, the lowest possible
ibuprofen dose should be given, whilst maintaining suitable
efﬁcacy.
The FLaring Arthralgia Relief Evaluation in episodic ﬂaring knee
pain (FLARE) study investigated the efﬁcacy, safety and tolerability
of a new lipid formulation of ibuprofen (Flarin®, Inﬁrst Healthcare)
1200 mg/day, and compared its effects with standard soft-gel
capsules (1200 mg or 2400 mg/day) over 5 days in patients
suffering episodic knee ﬂare pain. The lipid formulation fully dis-
solves ibuprofen within a lipid matrix (hard fat and glycerol mon-
olinoleate), which is anticipated to reduce the gastric effects which
are associated with conventional ibuprofen formulations, and may
reduce gastric irritation associated with high local ibuprofen con-
centrations. The 5-day treatment course is consistent with the
approved short-term over-the-counter treatment period before
patients are advised to seek medical advice (typically 5e10 days).
However, to ensure this study represented ‘real world’ usage, pa-
tients could receive a second 5-day treatment course if requested.
Method
The study comprised a multicentre, randomised, double-blind,
3-arm design to test for non-inferiority by comparing ibuprofen
1200 mg/day lipid formulation with standard ibuprofen soft-gel
capsules at a dose of 1200 mg/day or 2400 mg/day. It was con-
ducted at 27 centres, comprising general practitioner surgeries in
the UK and The Netherlands. Patients with a history of knee ﬂares
were identiﬁed by a variety of methods, including medical record
review and local advertising whereupon potential patients were
then referred to a local study site. Patients were screened to
determine study eligibility and were instructed to return to the
study site within 24 h if they experienced another knee ﬂare. The
study was approved by the central independent ethics committeeof each country (UK: NRES Committee East Midlands e North-
ampton; Netherlands: Independent Review Board Nijmegen). All
patients provided written informed consent.
Study population
Males or females aged 18e70 years with a history of 1 knee
ﬂare pain episodes in the previous 12 months (with or without
treatment), who experienced a new knee ﬂare episode with pain
severity 5 on a 0e10 numerical rating scale (NRS) and who
attended a baseline evaluationwithin 24 h of experiencing the new
knee ﬂare episode, were eligible for participation. Key exclusion
criteria were recent serious illness, fracture, signiﬁcant injury or
surgery to the knee, recent intra-articular treatment or systemic
corticosteroids, and use of any pain medication within 7 days of
study baseline.
Randomisation
Treatment was determined by a central 1:1:1 randomisation
schedule prepared using standard computer software with a
random seed number and a block size of six. This software in-
corporates a reproducible standard procedure for generating
random numbers. Medication was distributed to centres using
complete block numbers.
Treatment groups
Patients were randomised to one of three treatment arms:
 5-day treatment with 2 200 mg lipid ibuprofen capsules three
times daily (total daily dose 1200 mg)
 5-day treatment with 1  400 mg soft-gel ibuprofen capsule
plus 1  placebo capsule three times daily (total daily dose
1200 mg)
 5-day treatment with 2  400 mg soft-gel capsule ibuprofen
capsules three times daily (total daily dose 2400 mg)
All study drugs were produced by the same manufacturer on
behalf of Inﬁrst Healthcare and were presented as identical soft
white oval gelatin capsules to preserve blinding. Treatments were
taken every 6 h (i.e., morning, afternoon and evening) with half a
glass of water (2 h pre- or post-food). The study treatment dosewas
taken after completing the baseline assessments. After 5 days'
treatment (Course 1), patients returned to the study centre to
assess whether their knee ﬂare had been adequately controlled
(based on a pre-deﬁned 4-point scale). Eligible patients who
wanted further treatment after completing Course 1 could receive a
further 5-day treatment period (Course 2).
Outcomes
Primary study outcome was change from baseline in Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
pain subscale (normalised to 0e10 range) after 5 days' treatment.
This is a widely used and validated instrument for evaluating OA.22
The pain subscale is the most studied and reliable endpoint within
the WOMAC23,24 and the clinical experts involved in the study
design and authors considered the pain subscale to be the most
appropriate endpoint.
The main secondary outcome was change from baseline after 5
days in the Gastrointestinal Symptom Rating Scale (GSRS) based on
7-point Likert scale of 15 items.25 Other secondary endpoints
included assessment of WOMAC total score and subscale scores for
function and stiffness; average daily self-reported NRS scores (0e10
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reported swelling; patient's global assessment of the overall knee
ﬂare episode using a NRS (0e10 scale); and the proportion of pa-
tients achieving an OMERACT-OARSI response.26
Statistical analysis
Sample size: This was based on assessing non-inferiority of the
lipid 1200 mg capsule to the 1200 mg and 2400 mg soft-gel cap-
sules for change from baseline after 5 days' treatment in the
WOMAC pain score. The number of evaluable patients required to
test for non-inferiority was 146 per treatment group, assuming the
true treatment differencewas 0, the non-inferioritymarginwas 0.8,
and the SD was 2.1, using a 1-sided 2.5% alpha-level with 90% po-
wer. The choice of non-inferiority margin was based on the
WOMAC 0e10 NRS, translated from a score of 8 if based on a 0e100
visual analogue scale (VAS). An observed clinically important dif-
ference of 10e20 has been reported,27e29 and a meta-analysis of
randomised controlled NSAID clinical trials for OA knee pain30
showed the lower conﬁdence interval [CI] for the effect size was
7.4. A slightly higher value than the lower bound of this interval
(i.e., 8.0) was chosen due to the short duration of the trials included
in the meta-analysis.
Efﬁcacy parameters: All analyses were performed on the Full
Analysis Set (FAS), where treated patients without any post-
baseline data were excluded. No imputation was used for missing
data. An analysis of covariance (ANCOVA) was used to test the effect
of lipid 1200 mg on the change from baseline after 5 days' treat-
ment in the WOMAC pain scale score compared to the standard
formulations. The model included ﬁxed effects for treatment group
and centre (pooled where necessary) and baseline WOMAC pain
score as a linear covariate. Centres contributing <6 subjects to the
primary endpoint analysis were pooled based on geographical
location for analysis purposes, with small centres pooled with their
nearest neighbour and only occurred within each country. A
sensitivity analysis assessed the robustness of the primary
endpoint results to the method of handling missing data. This
analysis was performed on the randomised set including patients
excluded from the FAS, using a baseline observation carried for-
ward (BOCF) approach for patients with no on-treatment data.
Changes from baseline after 5 days' treatment in the GSRS total
score; WOMAC total, stiffness scale and function scale scores; GSRS
dimension scores; and patient's global assessment of outcomewere
analysed using the same methodology as the primary endpoint.Table I
Patient demographic characteristics (Treated Set)
Lipid 1200 mg Soft-g
Number of patients [N (%)] 148 (100.0) 155 (
Gender [N (%)]
Male 87 (58.8) 91 (5
Female 61 (41.2) 64 (4
Ethnicity [N (%)]
Asian 5 (3.4) 5 (3.2
Black 6 (4.1) 5 (3.2
White 131 (88.5) 142 (
Other 6 (4.1) 3 (1.9
Age (years)
Mean (SD) 51.6 (13.6) 51.7 (
Median (range) 53.5 (18, 70) 55.0 (
Age group [N (%)]
<65 years 114 (77.0) 130 (
65 years 34 (23.0) 25 (1
Index knee [N (%)]
Left 75 (50.7) 84 (5
Right 73 (49.3) 71 (4Daily NRS scores (scale of 0e10) were analysed using a mixed
model for repeated measures (MMRM) approach, with the analysis
including effects for treatment group, day, pooled centre, baseline
score and the treatment-by-day and baseline score-by-day inter-
action terms. The adjusted treatment group difference at each day
with the corresponding 95% CI was presented along with the P-
value. The proportion of patients achieving an OMERACT-OARSI
response,20 and proportion of patients in each of the knee ﬂare
categories after 5 days' treatment were analysed using a stratiﬁed
(by pooled centre) Cochran-Mantel-Haenszel (CMH) test. Time to
knee ﬂare resolution was compared using a Cox proportional haz-
ards model, stratiﬁed by centre (pooled where necessary). Time-to-
event analysis using a Cox proportional hazards model stratiﬁed by
pooled centre was used to estimate a hazard ratio. A stratiﬁed log-
rank test and KaplaneMeier estimates were used to support the
analyses.
Safety parameters: Planned safety analyses were descriptive.
Post-hoc statistical analyses formally tested for the difference be-
tween groups for all GI AEs and treatment-related GI AEs using the
CMH test.
Results
464 patients were randomised: 462 (99.6%) received treatment
between 17-Mar-2015 and 10-Aug-2016 (148 lipid 1200 mg, 155
soft-gel 1200 mg, 159 soft-gel 2400 mg). 58.9% of patients were
male and mean age was 52.2 years (79.7% aged <65). The left knee
was index in 53.5% of patients (Table I). Treatment groups were
broadly balanced at baseline regarding medical history. Overall,
256 patients (55.4%) were taking concomitant medications,
particularly for cardiovascular indications and diabetes; only a
small number of patients were taking paracetamol (0.4%), other
analgesic agents (<2.5%), or other agents that could cause GI upsets
(<10%).
Average patient compliance was >97% in all groups. Twenty-
three patients (5.0%) prematurely discontinued the study, with
similar numbers across the treatment groups. Two patients were
randomised but not treated (both lipid 1200 mg group). The most
common reason for premature discontinuation was ‘Other’ (10
patients [2.2%]) most frequently due to patients attending the
clinic early for their follow-up appointment (primarily due to
symptom resolution). Eight patients (1.7%) withdrew due to AEs,
two patients (0.4%) due to protocol deviation, and one patient
(0.2%) because knee ﬂare was resolved. Note: patients whoel 1200 mg Soft-gel 2400 mg Total
100.0) 159 (100.0) 462 (100.0)
8.7) 94 (59.1) 272 (58.9)
1.3) 65 (40.9) 190 (41.1)
) 3 (1.9) 13 (2.8)
) 2 (1.3) 13 (2.8)
91.6) 152 (95.6) 425 (92.0)
) 2 (1.3) 11 (2.4)
13.0) 53.3 (12.6) 52.2 (13.1)
18, 69) 56.0 (19, 69) 55.0 (18, 70)
83.9) 124 (78.0) 368 (79.7)
6.1) 35 (22.0) 94 (20.3)
4.2) 88 (55.3) 247 (53.5)
5.8) 71 (44.7) 215 (46.5)
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they did not have WOMAC at baseline and at least one on-
treatment (during the ﬁrst 5-day treatment course) assessment
of WOMAC pain score (or an important protocol violation for the
per protocol analysis). A total of 130 patients received a second
treatment course (44 lipid 1200 mg, 46 soft-gel 1200 mg, 40 soft-
gel 2400 mg) (Fig. 1).
Efﬁcacy results
After 5 days' treatment (completion of Course 1), meanWOMAC
pain subscale scores in the FAS were lower, indicating improve-
ment, in all three treatment groups: lipid 1200 mg change from
5.72 to 3.05, soft-gel 1200 mg from 5.60 to 3.26, and soft-gelFig. 1. CONSOR2400 mg from 5.61 to 2.82 (Table II). Differences in the adjusted
means between the lipid 1200 mg and soft-gel groups regarding
changes from baseline to the end of Course 1 were 0.26 (95%
CI: 0.69, 0.17) for the comparison lipid 1200 mg vs soft-gel
1200 mg, and 0.19 (95% CI: 0.24, 0.62) for the comparison lipid
1200 mg vs soft-gel 2400 mg. Since the whole of the 95% CIs lay
below the pre-deﬁned non-inferiority margin of 0.8 (but above the
superiority margin of 0), lipid 1200 mg was concluded to be non-
inferior both to soft-gel 1200 mg and 2400 mg (Table II, Fig. 2).
These FAS results were conﬁrmed by the supportive analysis in the
per protocol population, and by the sensitivity analysis using BOCF
for missing data (see online appendix). Comparison of thetwo soft-
gel groups showed that the non-inferiority criteria was not met
between the soft gel 1200 mg and 2400 mg groups. Furthermore,T diagram.
Table II
WOMAC scores after 5 days of treatment (Full Analysis Set)
Lipid 1200 mg Soft-gel 1200 mg Soft-gel 2400 mg
Number of patients in analysis set 145 152 155
Pain Scale score, n in analysis 145 152 155
Baseline score, mean (SD) 5.72 (1.64) 5.60 (1.69) 5.61 (1.64)
End of Course 1 (5 days) (mean [SD]) 3.05 (2.11) 3.26 (2.14) 2.82 (2.25)
Change from baseline to end of Course 1:
Adjusted mean (SE)* 2.42 (0.17) 2.16 (0.17) 2.61 (0.17)
95% conﬁdence interval* (2.76, 2.09) (2.49, 1.84) (2.94, 2.29)
Difference (lipid 1200 e soft-gel)
Adjusted mean (SE)* 0.26 (0.22) 0.19 (0.22)
(95% CI)*, P-value (superiority)*y (0.69, 0.17), 0.2327 (0.24, 0.62), 0.3799
Total score, n in analysis 144 149 154
Baseline score, mean (SD) 5.44 (1.74) 5.49 (1.62) 5.45 (1.70)
End of Course 1 (5 days) (mean [SD]) 2.94 (2.04) 3.13 (2.05) 2.77 (2.16)
Change from baseline to end of Course 1:
Adjusted mean (SE)* 2.32 (0.16) 2.18 (0.16) 2.53 (0.15)
95% conﬁdence interval* (2.63, 2.01) (2.49, 1.87) (2.84, 2.23)
Difference (lipid 1200 e soft-gel)
Adjusted mean (SE)* 0.14 (0.21) 0.21 (0.20)
(95% CI)*, P-value*y (0.54, 0.26), 0.4908 (0.19, 0.61), 0.3012
Stiffness score, n in analysis 144 152 154
Baseline score, mean (SD) 6.38 (1.91) 6.06 (1.96) 6.15 (2.03)
End of Course 1 (5 days) (mean [SD]) 3.29 (2.36) 3.57 (2.40) 3.18 (2.38)
Change from baseline to end of Course 1:
Adjusted mean (SE)* 2.78 (0.19) 2.38 (0.19) 2.80 (0.19)
95% conﬁdence interval* (3.16, 2.40) (2.75, 2.02) (3.17, 2.43)
Difference (lipid 1200 e soft-gel)
Adjusted mean (SE)* 0.40 (0.25) 0.02 (0.25)
(95% CI)*, P-value*y (0.88, 0.09), 0.1098 (0.47, 0.50), 0.9434
Function score, n in analysis 145 149 155
Baseline score, mean (SD) 5.25 (1.92) 5.39 (1.71) 5.32 (1.82)
End of Course 1 (5 days) (mean [SD]) 2.86 (2.05) 3.06 (2.09) 2.72 (2.17)
Change from baseline to end of Course 1:
Adjusted mean (SE)* 2.26 (0.16) 2.14 (0.16) 2.46 (0.15)
95% conﬁdence interval* (2.57, 1.95) (2.44, 1.83) (2.77, 2.16)
Difference (lipid 1200 e soft-gel)
Adjusted mean (SE)* 0.12 (0.20) 0.21 (0.20)
(95% CI)*, P-value*y (0.52, 0.28), 0.5598 (0.19, 0.60), 0.3056
WOMAC scores range from 0 (best outcome) to 10 (worst outcome).
Negative values indicate an improvement from baseline.
* ANCOVA on observed data including treatment, pooled centre and baseline WOMAC total score terms.
y Standard 2-sided 5% signiﬁcance level for superiority.
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gel 1200 mg is less effective than soft-gel 2400 mg, consistent with
expected dose-dependent beneﬁts. It is noteworthy that this
comparison was not formally pre-planned but was produced with
the statistical model output.
Mean GSRS total scores (main secondary efﬁcacy endpoint)
were low at baseline and only small changes were seen during the
study (adjustedmean changes: 0.08 for lipid 1200mg, 0.05 for soft-
gel 1200 mg, 0.13 for soft-gel 2400 mg). Differences in the adjusted
means for the comparison lipid 1200 mg vs soft-gel groups were
0.03 (95% CI: 0.08, 0.13) for soft-gel 1200 mg, and 0.05 (95%
CI: 0.16, 0.05) for soft-gel 2400 mg (Table III). Mean GSRS
dimension scores over time (i.e., other secondary endpoints) were
generally marginally higher or unchanged at the end of Course 1
compared with baseline, and none were statistically signiﬁcant.
For the additional secondary endpoints, meanWOMAC subscale
scores (total, stiffness and function scores) were all lower, indi-
cating improvement, at the end of Course 1 compared to baseline in
all three treatment groups. No statistically signiﬁcant differences
emerged between treatment groups regarding changes from
baseline to the end of Course 1 in any of the WOMAC subscale
scores analysed (Table II).
NRS scores for pain, stiffness, patient-nominated activity, and
swelling decreased each day from baseline until the end of Course 1
in all treatment groups, with patients reporting increased beneﬁts
each day over the 5-day treatment period. Results in the lipid1200 mg group tended to be numerically closer to those in the soft-
gel 2400mg group and higher than the soft-gel 1200mg group (not
statistically signiﬁcant). However, the difference between lipid
1200 mg and soft-gel 1200 mg for swelling reached nominal sta-
tistical signiﬁcance after treatment completion (adjusted mean
difference 0.4, 95% CI: 0.8, 0.0, P ¼ 0.04) (Fig. 3).
Mean global NRS assessment scores were similar for all treat-
ment groups at baseline, being approximately 50% lower (indi-
cating improvement) in each group after Course 1. Greatest
improvement was seen in the soft-gel 2400 mg group, followed by
the lipid 1200 mg group (3.1 in the soft-gel 2400 mg group, 2.8
in the lipid 1200 mg group, and 2.6 in the soft-gel 1200 mg
group). Differences in the adjusted means between the lipid
1200 mg and soft-gel groups in the changes from baseline to the
end of Course 1 were 0.2 (95% CI: 0.7, 0.3, P ¼ 0.43) for the
comparison lipid 1200 mg vs soft-gel 1200 mg, and 0.3 (95%
CI: 0.2, 0.7, P ¼ 0.30) for the comparison lipid 1200 mg vs soft-gel
2400 mg.
The percentage of responders according to OMERACT-OARSI
criteria was lowest in the soft-gel 1200 mg group (69.7%), fol-
lowed by 73.1% in the lipid 1200 mg group and 76.1% in the soft-gel
2400mg group. Similarly, most patients assessed their knee ﬂare as
controlled (i.e., fully controlled/under control) at the end of Course
1: 81 patients (55.9%) in the lipid 1200 mg group, 75 patients
(49.3%) in the soft-gel 1200 mg group, 92 patients (59.4%) in the
soft-gel 2400 mg group. The odds ratio for responders (i.e., fully
Fig. 2. Effect of treatment on WOMAC pain subscale scores.
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lipid 1200 mg vs soft-gel 1200 mg was 1.25 (95% CI: 0.76, 2.06),
indicating higher odds of response in the lipid 1200 mg group. The
odds ratio was below one for the comparison lipid 1200 mg vs soft-
gel 2400 mg (0.82, 95% CI: 0.50, 1.34) (Table IV).
Of the 130 patients who opted for a second course (total treat-
ment duration 10 days), knee ﬂare was fully controlled/under
control in 58 patients (44.6%): 22 patients (50.0%) in the lipid
1200 mg group, 12 patients (26.1%) in the soft-gel 1200 mg group,
and 24 patients (60.0%) in the soft-gel 2400 mg group.
Safety results
The number of patients with at least 1 AE was 54 (36.5%) in the
lipid 1200 mg group, 53 (34.2%) in the soft-gel 1200 mg group, and
65 (40.9%) in the soft-gel 2400 mg group. Most AEs were mild or
moderate in severity, with two patients per group experiencing
severe AEs. Overall, GI AEs were most frequently reported: 26.4% in
the lipid 1200 mg group, 30.3% in the soft-gel 1200 mg group, andTable III
Gastrointestinal Symptom Rating Scale (GSRS) scores after 5 days of treatment (Full Ana
Lipid 1200 mg
N ¼ 145
Total score, n in analysis 145
Change from baseline to end of Course 1:
Adjusted mean (SE)* 0.08 (0.04)
95% conﬁdence interval* (0.00, 0.16)
Difference (lipid 1200 e soft-gel)
Adjusted mean (SE)*
95% conﬁdence interval*, P-value*y
GSRS scores range from 1 (best outcome) to 7 (worst outcome).
Positive changes from baseline indicate deterioration in GSRS outcome.
* ANCOVA on observed data including treatment, pooled centre and baseline GSRS to
y Standard 2-sided 5% signiﬁcance level for superiority.33.3% in the soft-gel 2400mg group. The odds ratio for GI AEs in the
soft-gel 2400 mg group compared to the lipid 1200 mg group was
1.40 (95% CI: 0.85, 2.29), P ¼ 0.18 (post-hoc analysis).
The percentage of patients with drug-related AEs based on
Investigator blinded assessment was lower in the lipid 1200 mg
group (18.9% compared to 23.9% in the soft-gel 1200 mg group and
31.4% in the soft-gel 2400 mg group). The most frequently reported
drug-related AEs were GI disorders (16.2% for lipid 1200 mg, 22.6%
for soft-gel 1200 mg, 28.3% for soft-gel 2400 mg) (Table V). The
odds ratio in the soft-gel 2400 mg group compared to the lipid
1200 mg group for drug-related GI AEs was statistically signiﬁcant:
2.04 (95% CI: 1.17, 3.56, P ¼ 0.01) (post-hoc analysis).
Nine patients discontinued study drug due to AEs, the most
common being diarrhoea (three patients), abdominal discomfort
(two patients), and dyspepsia (two patients). Five discontinuations
were in the soft-gel 2400 mg group. One patient in the soft-gel
2400 mg group experienced a serious, severe AE of worsening
endometriosis and led to study drug discontinuation, although this
was considered unrelated to treatment.lysis Set)
Soft-gel 1200 mg
N ¼ 152
Soft-gel 2400 mg
N ¼ 155
149 154
0.05 (0.04) 0.13 (0.04)
(0.03, 0.14) (0.05, 0.21)
0.03 (0.05) 0.05 (0.05)
(0.08, 0.13), 0.6331 (0.16, 0.05), 0.3373
tal score terms.
Fig. 3. Change from baseline in self-reported symptoms (NRS evaluation).
Table IV
Responses after 5 days, as assessed by OMERACT-OARSI criteria and knee ﬂare response Categories
Lipid 1200 mg
N ¼ 145
Soft-gel 1200 mg
N ¼ 152
Soft-gel 2400 mg
N ¼ 155
OMERACT-OARSI Response, n in analysis 145 152 155
Number (%) of responders 106 (73.1) 106 (69.7) 118 (76.1)
95% conﬁdence interval (%)* (65.1, 80.1) (61.8, 76.9) (68.6, 82.6)
Difference (lipid 1200 e soft-gel)y
Odds ratio 1.135 0.833
95% conﬁdence interval (0.674, 1.914) (0.488, 1.422)
P-value 0.6349 0.5056
Knee Flare Response Categories, n in analysis 145 152 155
End of Course 1 (5 days) score [N (%)]:
 Fully controlled 19 (13.1) 17 (11.2) 27 (17.4)
 Under control 62 (42.8) 58 (38.2) 65 (41.9)
 Partially controlled 44 (30.3) 51 (33.6) 48 (31.0)
 Not under control 20 (13.8) 26 (17.1) 15 (9.7)
Number (%) of responders at the end of Course 1 (5 days): 81 (55.9) 75 (49.3) 92 (59.4)
95% conﬁdence interval (%)* (47.4, 64.1) (41.1, 57.6) (51.2, 67.2)
Difference (lipid 1200 e soft-gel)y
Odds ratio 1.251 0.820
95% conﬁdence interval (0.759, 2.062) (0.501, 1.341)
P-value 0.3763 0.4204
OMERACT-OARSI response: Response deﬁned as improvement in WOMAC pain or function of 50% with change of 2, or improvement in at least two of: 1) pain 20% with
change of 1, 2) function 20% with change of 1, 3) global assessment 20% with change of 1.
Knee ﬂare response categories: Response deﬁned as knee ﬂare category of ‘Fully controlled’ or ‘Under control’.
Odds ratios >1 indicate higher odds of response in lipid 1200.
* Exact (Clopper-Pearson) conﬁdence interval for a binomial proportion.
y CMH statistics controlling for pooled centre.
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Table V
Drug-related adverse events reported for >1% of patients in any treatment group (Treated Set)
System Organ Class Preferred term Lipid 1200 mg
N (%)
Soft-gel 1200 mg
N (%)
Soft-gel 2400 mg
N (%)
Number of patients 148 (100.0) 155 (100.0) 159 (100.0)
Number of patients with at least one drug-related AE 28 (18.9) 37 (23.9) 50 (31.4)
Gastrointestinal disorders 24 (16.2) 35 (22.6) 45 (28.3)
Diarrhoea 5 (3.4) 8 (5.2) 8 (5.0)
Nausea 7 (4.7) 7 (4.5) 8 (5.0)
Abdominal distension 4 (2.7) 4 (2.6) 12 (7.5)
Abdominal discomfort 7 (4.7) 3 (1.9) 9 (5.7)
Dyspepsia 3 (2.0) 7 (4.5) 11 (6.9)
Constipation 4 (2.7) 2 (1.3) 6 (3.8)
Flatulence 2 (1.4) 5 (3.2) 5 (3.1)
Abdominal pain upper 2 (1.4) 8 (5.2) 5 (3.1)
Gastro-oesophageal reﬂux disease 1 (0.7) 5 (3.2) 7 (4.4)
Eructation 3 (2.0) 4 (2.6) 5 (3.1)
Gastrointestinal motility disorder 1 (0.7) 3 (1.9) 2 (1.3)
Abdominal pain 2 (1.4) 3 (1.9) 6 (3.8)
Gastrointestinal sounds abnormal 3 (2.0) 4 (2.6) 4 (2.5)
Defaecation urgency 1 (0.7) 1 (0.6) 2 (1.3)
Faeces hard 0 (0.0) 1 (0.6) 3 (1.9)
Abdominal tenderness 1 (0.7) 0 (0.0) 2 (1.3)
General disorders and administration site conditions 1 (0.7) 1 (0.6) 4 (2.5)
Nervous system disorders 3 (2.0) 2 (1.3) 1 (0.6)
Headache 2 (1.4) 2 (1.3) 0 (0.0)
Vascular disorders 2 (1.4) 0 (0.0) 0 (0.0)
Hypertension 2 (1.4) 0 (0.0) 0 (0.0)
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We believe this is the ﬁrst large-scale study to investigate
episodic knee pain ﬂares in primary care patients. The FLARE study
was designed to address the need for effective, short-term treat-
ment for relief of ﬂaring knee pain. The primary study endpoint was
change from baseline after 5 days' treatment in the WOMAC pain
scale score, and the primary analysiswas the test for non-inferiority
between treatments. The outcome of the primary analysis was that
improvements in WOMAC pain scale score were observed in all
three treatment groups and lipid 1200 mg treatment was non-
inferior to soft-gel 1200 mg and 2400 mg. This ﬁnding was
conﬁrmed by the outcome of the supportive analyses. For NRS
endpoints, results for lipid 1200 mg were remarkably consistent
with the soft-gel 2400 mg group.
Knee OA is a leading cause of knee pain and is associated with
disability and functional limitations in adults.31 It has been ranked
alongside heart disease, depressive symptomatology and stroke
for resulting levels of disability.32 Up to one-third of older adults
(>55 years) show radiological evidence of knee OA, indicating an
annual prevalence of 25%.2,33 The study patient cohort is younger
than normally found in typical OA trials and was recruited from
primary care settings, suggesting representation of early clinical
phase OA.
NSAIDs are commonly used to treat knee pain and OA, most
frequently ibuprofen14,15 which is typically administered at a daily
dose of 1200 mg.34 The higher 2400 mg dose has shown additional
anti-inﬂammatory properties and may be used for conditions such
as rheumatoid arthritis and ankylosing spondylitis. A meta-analysis
assessed the effectiveness of different preparations and doses of
NSAIDs on OA pain and showed all preparations, irrespective of
dose, improved point estimates of pain symptoms compared with
placebo, with higher NSAID dosages being most effective.35
The GSRS total score was the key secondary study endpoint
because most common AEs associated with ibuprofen are GI-
related. However, mean GSRS total scores were low at baseline
and only small changes were seen during the study. Mean GSRS
dimension scores (abdominal pain, constipation, diarrhoea, indi-
gestion, reﬂux) also showed only small changes, with nostatistically signiﬁcant differences between the treatment groups,
suggesting the GSRS may not be an appropriate tool to detect
changes in GI symptoms in this patient population, or may be un-
suitable for short-term studies.
Pain, stiffness, patient-nominated activity, and swelling NRS
scores decreased daily from baseline until the end of Course 1 in all
treatment groups, with patients reporting increased beneﬁts each
day throughout the 5-day treatment period. Although differences
between treatment groups did not reach statistical signiﬁcance,
there was a trend for the results in the lipid 1200 mg group to be
numerically closer to those in the soft-gel 2400 mg group, and
higher than those in the soft-gel 1200 mg group. It is noteworthy
that the difference between lipid 1200 mg and soft-gel 1200 mg
groups for swelling reached nominal statistical signiﬁcance after
treatment, and the WOMAC stiffness score also showed a closer
result to the soft-gel 2400 mg group. This could indicate an anti-
inﬂammatory effect of the lipid 1200 mg treatment that was
closer to the soft-gel 2400 mg group. However, these ﬁndings
require further investigation.
Responder analyses also supported the primary and secondary
efﬁcacy analyses, with responder rates according to OMERACT-
OARSI criteria being lowest in the soft-gel 1200 mg group
(69.7%), followed by the lipid 1200 mg group (73.1%) and the soft-
gel 2400mg group (76.1%). The percentage of responders per group
was relatively high compared with published data from OA trials
where a responder rate of approximately 60% has been reported.36
This probably reﬂects the patient population in the current study
that comprised patients with short-term, self-limiting knee pain
compared to usual OA populations.
Although the mechanism of action for the lipid formulation has
yet to be fully deﬁned, lipid drug delivery systems appear to target
the lymphatic part of the immune system rather than reaching the
systemic circulation via the portal vein and liver from the small
intestine as is commonly the case with oral treatments.37 This
means there is a reduction in ﬁrst-pass metabolism and potential
for higher lymphatic-mediated ibuprofen lipoprotein fraction drug
exposure.37 Theoretically, the trend of enhanced efﬁcacy seen in
the lipid 1200 mg group compared with the soft-gel 1200 mg
group may be due to lipid-mediated lymphatic targeting of the
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hypothesis.
The study treatments were well-tolerated and no new safety
issues emerged. AEs occurred with lowest frequency in the lipid
1200 mg group and at highest frequency in the soft-gel 2400 mg
group. The most common AEs/drug-related AEs were GI disorders,
a known ibuprofen adverse effect. A post-hoc analysis revealed
signiﬁcantly more drug-related GI AEs in the soft-gel 2400 mg
group compared to the lipid 1200mg group (P¼ 0.01), indicating as
expected that the lipid 1200 mg formulation is likely to be gastro-
sparing. No drug-related cardiovascular events were noted which
was unsurprising given the short treatment duration. However,
given that the cardiovascular effects of ibuprofen are dose and
time-related,18,19 this new lipid ibuprofen formulation may be ad-
vantageous in reducing dose-related AEs in patients with cardio-
vascular risk factors. Further long-term studies are needed to
substantiate this hypothesis.
This was a ground-breaking study as patients were recruited
from the community setting and treated within 24 h of developing
spontaneous ﬂaring knee pain. However, limitations to the study
design included the lack of a placebo arm, although ibuprofen has
been unequivocally shown to have a dose response for pain
reduction and we intended to detect treatment differences rather
than conﬁrming previously proven efﬁcacy. Patients were only
followed-up for a short time; future studies may incorporate a
longer follow-up period to assess duration of post-knee ﬂare res-
olution. However, patients with other clear causes of knee ﬂares
were excluded, which narrows the study population towards the
early stage OA population.
In conclusion, a new low-dose lipid formulation of ibuprofen
1200 mg/day was non-inferior to standard soft-gel ibuprofen cap-
sules 1200 mg/day and 2400 mg/day in relieving ﬂaring knee pain.
The outcome of the primary efﬁcacy analysis was robust and sup-
ported by secondary efﬁcacy analyses. The response in the soft-gel
groups appeared to be dose-related, with the soft-gel 1200 mg
group being inferior to the soft-gel 2400 mg group. For the NRS
assessments, the lipid 1200 mg group was more closely aligned
with the soft-gel 2400 mg group than the soft-gel 1200 mg group.
The lipid 1200 mg treatment also showed numerically greater
improvements in other secondary endpoints, such as swelling and
stiffness, compared to soft-gel 1200 mg and comparable results to
the 2400 mg group. This is the ﬁrst time over such a short duration
that a lipid formulation of ibuprofen 1200 mg/day has been shown
to be as effective as ibuprofen 2400mg/day in relieving ﬂaring joint
pain and may provide information for patient self-management
together with guidance for clinicians on treatment of early
stage OA.
Author contributions
Professor Sita MA Bierma-Zeinstra (SBZ)
John Brew (JB)
Rosamund Wilson (RW)
Karen Stoner (KS)
Anthony Kilbourn (AK)
Professor Philip G Conaghan (PGC)
 Involved in the conception and design of the study, or acquisi-
tion of data, or analysis and interpretation of data: SBZ, JB, KS,
RW, AK, PGC.
 Drafting the article or revising it critically for important intel-
lectual content: SBZ, JB, KS, RW, AK, PGC.
 Final approval of the version to be submitted: SBZ, JB, KS, RW,
AK, PGC.
 All authors take responsibility for the integrity of the work as a
whole, from inception to ﬁnished article.Competing interest statement
PGC has been a consultant for Abbvie, Flexion Therapeutics, Inﬁrst,
Medivir andMerck Serono. PGC is supported in part by the National
Institute for Health Research (NIHR) Leeds Biomedical Research
Centre. The views expressed are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health.
JB, KS and AK are employees of Inﬁrst Healthcare Ltd. RW is a
statistical consultant to Inﬁrst Healthcare.
SBZ declares that her institution received consultancy fees from
Inﬁrst Healthcare with respect to this study.
Role of the funding source
This study was funded by inﬁrst Healthcare, manufacturers of the
new lipid formulation of ibuprofen (Flarin®). This funding inclu-
dedinvolvement in the design of the study, the statistical analysis,
andthe drafting of this manuscript.
Acknowledgments
Medical writing support was provided by Debbie Jordan Ltd,
with funding from inﬁrst Healthcare.
Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.joca.2017.09.002.
References
1. McAlindon TE, Cooper C, Kirwan JR, Dieppe PA. Knee pain
and disability in the community. Br J Rheumatol 1992;31:
189e92.
2. O'Reilly SC, Muir KR, Doherty M. Screening for pain in knee
osteoarthritis: Which question? Ann Rheum Dis 1996;55:
931e3.
3. Favero M, Ramonda R, Goldring MB, Goldring SR, Punzi L. Early
knee osteoarthritis. RMD Open 2015;1(Suppl 1):e000062.
4. Hawker GA, Stewart L, French MR, Cibere J, Jordan JM, March L.
Understanding the pain experience in hip and knee osteoar-
thritis e an OARSI/OMERACT initiative. Osteoarthr Cartil
2008;16:415e22.
5. Marty M, Hilliquin P, Rozenberg S, Valat JP, Vignon E, Coste P,
et al. Validation of the KOFUS (Knee Osteoarthritis Flare-Ups
Score). Jt Bone Spine 2009;76(3):268e72.
6. Osteoarthritis: Care and Management Clinical Guideline
[CG177] Published date: February 2014. Accessed 10-Feb-
2017, at https://www.nice.org.uk/guidance/cg177.
7. Leffondre K, Abrahamowicz M, Regeasse A, Hawker GA,
Badley EM, McCusker J, et al. Statistical measures were pro-
posed for identifying longitudinal patterns of change in
quantitative health indicators. J Clin Epidemiol 2004;57(10):
1049e62.
8. Conrozier T, Mathieu P, Vignon E, Piperno M, Rinaduo M.
Differences in the osteoarthritic synovial ﬂuid composition
and rheology between patients with or without ﬂare: a pilot
study. Clin Exp Rheumatol 2012;30:729e34.
9. Zhang Y, Nevitt M, Niu J, Lewis C, Torner J, Guermazi A, et al.
Fluctuation of knee pain and changes in bone marrow lesions,
effusions, and synovitis on magnetic resonance imaging.
Arthritis Rheum 2011;63(3):691e9.
10. Bannuru R, Schmid CH, Kent DM, Vaysbrot EE, Wong JB,
McAlindon TE. Comparative effectiveness of pharmacologic
interventions for knee osteoarthritis: a systematic review and
network meta-analysis. Ann Intern Med 2015;162:46e54.
S.M.A. Bierma-Zeinstra et al. / Osteoarthritis and Cartilage 25 (2017) 1942e1951 195111. Smith SR, Deshpande BR, Collins JE, Katz JN, Losina E.
Comparative pain reduction of oral non-steroidal anti-in-
ﬂammatory drugs and opioids for knee osteoarthritis: sys-
tematic analytic review. Osteoarthr Cartil 2016;24:962e72.
12. Kennedy S, Moran M. Pharmacological treatment of osteoar-
thritis of the hip and knee. BCMJ 2010;52(8):404e9.
13. Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin C-WC,
Day RO, et al. Efﬁcacy and safety of paracetamol for spinal pain
and osteoarthritis: systematic review and meta-analysis of
randomised placebo controlled trials. BMJ 2014;350:h1225.
14. Bushra R, Aslam N. An overview of clinical pharmacology of
ibuprofen. Oman Med J 2010;25(3):155e1661.
15. Rainsford KD. History and development of ibuprofen. In:
Rainsford KD, Ed. Ibuprofen. A Critical Bibliographic Review.
London: Taylor and Francis; 1999:1e24.
16. Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA. The
safety proﬁle of non prescription ibuprofen in multiple-dose
use: a meta-analysis. J Clin Pharmacol 1999;39:520e32.
17. Moore N, Pollack C, Butkerait P. Adverse drug reactions and
drug-drug interactions with over-the-counter NSAIDs. Ther
Clin Risk Manag 2015;11:1061e75.
18. FDA Safety Announcement, http://www.fda.gov/Drugs/
DrugSafety/ucm451800.htm.
19. EMA/H/A-31/140, EMA/PRAC/182074/2015 Pharmacovigi-
lance Risk Assessment Committee. Recommendation of the
Pharmacovigilance Risk Assessment Committee Pursuant to
Article 31 of Directive 2001/83/EC Resulting from Pharmaco-
vigilance Data, for Medicinal Products Containing Ibuprofen
and Dexibuprofen (Systemic Formulations) 2015.
20. Submitted to U.S FDAOARSI: Osteoarthritis e a Serious Disease
December 1, 2016.
21. Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A,
Garbe E, et al. Risk of acute myocardial infarction with NSAIDs
in real world use: bayesian meta-analysis of individual patient
data. BMJ 2017;357:j1909.
22. Bellamy N, Buchanan WW, Goldsmith CH, Stitt L. Validation
study of WOMAC: a health status instrument for measuring
clinically important patient relevant outcomes to antirheu-
matic drug therapy in patients with osteoarthritis of the hip or
knee. J Rheumatol 1988;15:1833e40.
23. Woolacott NF, Corbett MS, Rice SJC. The use and reporting of
WOMAC in the assessment of the beneﬁt of physical therapies
for the pain of osteoarthritis of the knee: ﬁndings from a
systematic review of clinical trials. Rheumatology 2012;51:
1440e6.
24. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD,
Arden NK, et al. OARSI recommendations for the management
of hip and knee osteoarthritis Part III: changes in evidence
following systematic cumulative update of research published
through January 2009. Osteoarthr Cartil 2010;18:476e99.25. Svedlund J, Sj€odin I, Dotevall G. GSRS - a clinical rating scale for
gastrointestinal symptoms in patients with irritable bowel
syndrome and peptic ulcer disease. Dig Dis Sci 1988;33(2):
129e34.
26. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N,
Hochberg M, et al. OMERACT-OARSI initiative: osteoarthritis
Research Society International set of responder criteria for
osteoarthritis clinical trials revisited. Osteoarthr Cartil
2004;12:389e99.
27. Angst F, Aeschlimann A, Michel BA, Stucki G. Minimal clinically
important rehabilitation effects in patients with osteoarthritis
of the lower extremities. J Rheumatol 2002;29(1):131e8.
28. Bijlsma JW. Patient centred outcomes in osteoarthritis. Ann
Rheum Dis 2005;64(1):1e2.
29. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N,
et al. Evaluation of clinically relevant changes in patient re-
ported outcomes in knee and hip osteoarthritis: the minimal
clinically important improvement. Ann Rheum Dis 2005;64(1):
29e33.
30. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal
anti-inﬂammatory drugs, including cyclo-oxygenase-2 in-
hibitors, in osteoarthritic knee pain: meta-analysis of rando-
mised placebo controlled trials. BMJ 2004;329(7478):1317.
31. Zeni Jr JA, Axe MJ, Snyder-Mackler L. Clinical predictors of
elective total joint replacement in persons with end-stage
knee osteoarthritis. BMC Musculoskelet Disord 2010;11:86.
32. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y,
Wilson PWF, et al. The effects of speciﬁc medical conditions on
the functional limitations of elders in the Framingham Study.
Am J Public Health 1994;84:351e8.
33. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in
older adults: a review of community burden and current use of
primary health care. Ann Rheum Dis 2001;60:91e7.
34. Schiff M, Minic M. Comparison of the analgesic efﬁcacy and
safety of nonprescription doses of naproxen sodium and
ibuprofen in the treatment of osteoarthritis of the knee.
J Rheumatol 2004;31(7):1373e83.
35. Da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S,
Jüni P, et al. Effectiveness of non-steroidal anti-inﬂammatory
drugs for the treatment of pain in knee and hip osteoarthritis:
a network meta-analysis. Lancet 2016;387(10033):2093e105.
36. Bingham III CO, Smugar SS, Wang H, Peloso PM, Gammaitoni A.
Predictors of response to cyclo-oxygenase-2 inhibitors in
osteoarthritis: pooled results from two identical trials
comparing Etoricoxib, Celecoxib, and placebo. Pain Med
2011;12:352e61.
37. Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery
systems and intestinal lymphatic drug transport: a mecha-
nistic update. Adv Drug Deliv Rev 2008;60(6):702e16.
